MorphoSys AG

Type: Company
Name: MorphoSys AG
Nationality: Germany
Web Address: http://www.morphosys.com/
First reported 8 hours ago - Updated 8 hours ago - 1 reports

MorphoSys AG To Host Q1 2014 Conference Call On 29 April 2014

(GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first three months' 2014 results on 29 April 2014 at 7:00 am CEST. Help employers find you! Check out all the jobs and post your resume. ... [Published BioSpace - 8 hours ago]
Entities: MorphoSys AG, TecDAX
First reported 12 hours ago - Updated 11 hours ago - 1 reports

MorphoSys to Host Q1 2014 Conference Call on 29 April 2014

World News: 13:10 GMT Wednesday 23rd April 2014 . [ MorphoSys AG via Globe Newswire via SPi World News ]This storyMARTINSRIED and MUNICH, Germany, April 23, 2014 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish ... [Published SPi World News - 12 hours ago]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Treating Refractory Hematological Malignancies: Multiple Myeloma (MM)

The report (ToC) provides an overview of the therapies for Multiple Myeloma (Newly diagnosed – NDMM and relapsed/ refractory – RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts. The report highlights ... [Published ListFree.Org - Apr 18 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

STOCKS NEWS EUROPE-Germany's Morphosys up on Deutsche Bank note

Shares in biotech company Morphosys (Xetra: MOR.DE - news ) soar 7.3 percent to 59.49 euros,making them the biggest gainers on the German technology TECDAX indexafter Deutsche Bank (Xetra: DBK.DE - news ) increases its price target to 81 euros from 64 ... [Published Yahoo! UK and Ireland - Apr 16 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.05.2014 in München mit dem Ziel der europaweiten

MorphoSys AG: Announcement of the Convening of the AGM in Munich/Germany on 23 M mehr...03.04.2014MorphoSys AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr mehr...03.04.2014MorphoSys AG: Announcement of the Convening of the AGM ... [Published Quoteline - Apr 11 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

Xencor Inc.: Current Biotech Uncertainty Is An Opportunity

SummaryAs of closing April 2, Xencor is trading nearly 30% below the mean target of $16.30 and 20% below its 52wk high of $13.90 in mid-march before the recent disruption. Their bispecific antibody (bAb) leads are very promising, uniquely allowing fine ... [Published Seeking Alpha - Apr 03 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

MORPHOSYS : Biametrics Successfully Finalizes Feasibility Study with MorphoSys in the Area of High-Throughput Antibody Screening

The feasibility study clearly demonstrated the advantages of b-screen to speed up the overall antibody screening process using the microarray format. Recently, Biametrics launched their b-screen device for high-throughput biomolecular interaction scr ... [Published 4 Traders - Apr 02 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M

Mar 31, 2014 (Menafn - M2 PRESSWIRE via COMTEX) --The report provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current ... [Published MENAFN - Mar 31 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Director's Dealings announcement according to §15a WpHG (the German Securities Trading Act)

MorphoSys AG /Director's Dealings announcement according to §15a WpHG (the German SecuritiesTrading Act). Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.Details of the ... [Published Reuters - Mar 28 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars

Research and Markets (http://www.researchandmarkets.com/research/234sqv/global) has announced the addition of the "" report to their offering. Innovations have contributed to the availability of a range of new treatments for diseases resulting in improvements ... [Published Individual.com - Mar 27 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 2 reports

Research and Markets: Concise Analysis on Treating Refractory Hematological Malignancies for Multiple Myeloma

06:15 AM Eastern Daylight TimeDUBLIN--( BUSINESS WIRE )-- Research and Markets ( http://www.researchandmarkets.com/research/r8c39w/treating )has announced the addition of the "ConciseAnalysis on Treating Refractory Hematological Malignancies for Mult ... [Published Business Wire - Mar 26 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 2 reports

XENCOR : to Present at 21st Annual BioCentury Future Leaders in the Biotech Industry Conference

/PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, ... [Published 4 Traders - Mar 24 2014]

Quotes

...Greciet, CEO at BioAlliance and future leader of the combined company, called the merger "atypical," but thinks it works well for both parties. "It will make us bigger and stronger in negotiations and in the search for partnerships in different territories worldwide" Greciet told the media on a call attended by Bloomberg . Both companies have retained the rights to their pipeline products in Europe...
"The recent sell-off in shares appears fundamentally unjustified and largely"
...of our technology offering partners an opportunity to create best-in-class therapeutics," said Bassil Dahiyat , Ph D , President and CEO of Xencor. "By selectively licensing our XmAb technology, we believe we create value in non-core areas, thus allowing us to focus on advancing our key internal development programs."
...It is has shown in a Phase 1/2a trial " encouraging signs of preliminary anti-tumor activity and an acceptable safety and tolerability profile in patients with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)." As a result it is being actively investigated in 3 Phase 2 clinical trials in B-cell acute lymphoblastic leukemia (B-ALL), CLL, and non-Hodgkin's Lymphoma...

More Content

All (67) | News (51) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (15)
sort by: Date | Relevance
MorphoSys AG To Host Q1 2014 Conference Call On... [Published BioSpace - 8 hours ago]
MorphoSys to Host Q1 2014 Conference Call on 29... [Published SPi World News - 12 hours ago]
MorphoSys to Host Q1 2014 Conference Call on 29... [Published GlobeNewswire: Acquisitions News - 12 hours ago]
Dermatological Drugs Market Forecast 2014-2024 [Published Individual.com - Apr 22 2014]
Refractory Chronic Lymphocytic Leukemia CLL Glo... [Published BioPortfolio - Apr 22 2014]
Treating Refractory Hematological Malignancies:... [Published ListFree.Org - Apr 18 2014]
Global Pharmaceutical & Biotechnology Outlook 2... [Published ListFree.Org - Apr 18 2014]
Nasdaq volatility delays IPO, Almirall pulls dr... [Published FierceBiotech - Apr 18 2014]
Cohen’s Point72 Asset Management buys a stake i... [Published Yahoo! Finance - Apr 17 2014]
Heptares at Upcoming Diabetes and Neuroscience ... [Published Michigan Live - Apr 16 2014]
STOCKS NEWS EUROPE-Germany's Morphosys up on De... [Published Yahoo! UK and Ireland - Apr 16 2014]
Bio-Rad Buys GnuBio - Analyst Blog [Published Nasdaq - Apr 14 2014]
Bio-Rad Buys GnuBio [Published Zacks.com - Apr 14 2014]
New Report Available: Acute Lymphocytic Leukemi... [Published SBWire - Apr 11 2014]
MorphoSys AG: Announcement of the Convening of ... [Published GlobeNewswire: Advertising News - Apr 11 2014]
MorphoSys AG: Bekanntmachung der Einberufung zu... [Published Quoteline - Apr 11 2014]
Now Available: Non-Hodgkin Lymphoma - Pipeline ... [Published SBWire - Apr 10 2014]
Xencor Receives Milestone Payment from Merck fo... [Published ADVFN India - Apr 10 2014]
Discount Packages on Global Trends and Developm... [Published PR.com Press Releases - Apr 04 2014]
Discount Packages on Global Trends and Developm... [Published ListFree.Org - Apr 04 2014]
Xencor Inc.: Current Biotech Uncertainty Is An ... [Published Seeking Alpha - Apr 03 2014]
MORPHOSYS : Biametrics Successfully Finalizes F... [Published 4 Traders - Apr 02 2014]
Flow Cytometry Market (Products, Application, T... [Published TheStreet.com - Apr 02 2014]
Treating Refractory Hematological Malignancies ... [Published MENAFN - Mar 31 2014]
MorphoSys to Present at Two Upcoming Investor C... [Published GlobeNewswire: Acquisitions News - Mar 31 2014]
Director's Dealings announcement according to §... [Published Reuters - Mar 28 2014]
XENCOR : Showcases Bispecific Antibody Programs... [Published 4 Traders - Mar 28 2014]
EuroBiotech: Merck KGaA R&D chief exits, Sobi d... [Published FierceBiotech - Mar 28 2014]
Global Pharmaceutical and Biotechnology Outlook... [Published Individual.com - Mar 27 2014]
Research and Markets: Concise Analysis on Treat... [Published BusinessWeek - Mar 26 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Discount Packages on Global Trends and Developm... [Published PR.com Press Releases - Apr 04 2014]
New York, NY, April 04, 2014 --( PR.com )-- The global biotechnology and pharmaceutical market have seen significant positive sentiments in the recent years, especially with innovation contributing to the availability of a range of new treatments for ...
1

Press Releases

sort by: Date | Relevance
MorphoSys to Host Q1 2014 Conference Call on 29... [Published GlobeNewswire: Acquisitions News - 12 hours ago]
MorphoSys AG: Announcement of the Convening of ... [Published GlobeNewswire: Advertising News - Apr 11 2014]
MorphoSys to Present at Two Upcoming Investor C... [Published GlobeNewswire: Acquisitions News - Mar 31 2014]
MorphoSys to Present at Four Upcoming Investor ... [Published GlobeNewswire: Acquisitions News - Mar 03 2014]
MorphoSys to Start Share Buy-Back Program [Published GlobeNewswire: Acquisitions News - Mar 03 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.